2seventy bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Trials    News 


12345»
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Blenrep (belantamab mafodotin) / GSK
    Journal:  The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. (Pubmed Central) -  Jan 10, 2022   
    Prolonged cytopenia requiring hematopoietic rescue occurred in 2% (3/127) with 2 fatalities. BCMA targeting antibody drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies have demonstrated clinical activity in myeloma patients and represent novel therapies in multiple myeloma treatment paradigm.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #241; Author: Doris K Hansen, MD 1; Alexandria M Shrewsbury, MS, CCRC 1; Lauren Peres, MPH, PhD 2; Jessica Provencher, BS 1; Christina Copponex, MSN, APRN, FNP-C 1; Krista Kottra, MSN, APRN, FNP-C 1; Rebecca Gonzalez, PharmD, BCOP 3; Taiga Nishihori, MD 1; Hien Liu, MD 1; Jason Brayer, MD, PhD 4; Omar Castaneda, MD 1; Brandon Jamaal Blue, MD 4; Leonel Ochoa, MD 1; Ciara Freeman, MD 1; Jennifer Logue, MD 1; Hany Elmariah, MD 1; Rawan G Faramand, MD 1; Michael D Jain, MD, PhD 1; Aleksandr Lazaryan, MD, PhD, MPH 1; Nelli Bejanyan, MD 1; Lia Elena Perez, MD 1; Michael L. Nieder, MD 1; Asmita Mishra, MD 1; Joseph A. Pidala, MD, PhD 1; Marco L. Davila, MD, PhD 1; Kenneth Shain, MD, PhD 4; Rachid Baz, MD 4; Melissa Alsina, MD 1; Frederick L. Locke, MD 1;    
    These data support further investigation of the impact of tumor burden and immune dysregulation, which may uncover exploitable mechanisms to improve ide-cel outcomes in MM. Updated analysis with additional patients will be presented.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #243; Author: Doris K Hansen, MD 1; Alexandria M Shrewsbury, MS, CCRC 1; Lauren Peres, MPH, PhD 2; Rebecca Gonzalez, PharmD, BCOP 3; Christina Copponex, MSN, APRN, FNP-C 1; Krista Kottra, MSN, APRN, FNP-C 1; Jessica Provencher, BS 1; Taiga Nishihori, MD 1; Hien Liu, MD 1; Jason Brayer, MD, PhD 4; Omar Castaneda, MD 1; Brandon Jamaal Blue, MD 4; Leonel Ochoa, MD 1; Ciara Freeman, MD 1; Jennifer Logue, MD 1; Hany Elmariah, MD 1; Rawan G Faramand, MD 1; Michael D Jain, MD, PhD 1; Aleksandr Lazaryan, MD, PhD, MPH 1; Nelli Bejanyan, MD 1; Lia Elena Perez, MD 1; Michael L. Nieder, MD 1; Asmita Mishra, MD 1; Joseph A. Pidala, MD, PhD 1; Marco L. Davila, MD, PhD 1; Kenneth Shain, MD, PhD 4; Rachid Baz, MD 4; Frederick L. Locke, MD 1; Melissa Alsina, MD 1;    
    Longer follow-up, larger number of patients, and correlative studies on CAR T kinetics are required to establish significance of obesity on CAR T outcomes. Updated analysis with additional patients will be presented.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Breyanzi (lisocabtagene maraleucel) / BMS, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #248; Author: Samer Al Hadidi, MD, MS, FACP 1; Carolina Schinke, MD 2; Sharmilan Thanendrarajan, MD 2; Maurizio Zangari, MD 2; Frits Van Rhee, MD PhD MRCP MRCPath 3;    
    CONCLUSIONS Blacks are under-represented in clinical trials that supported CAR-T therapies for various hematological malignancies especially in MM. Efforts should be made to enroll more Blacks in clinical trials that include novel, potentially beneficial CAR-T products.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Actemra IV (tocilizumab) / Roche, JW Pharma
    Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel) (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #297; Author: Nausheen Ahmed, MD 1; Al-Ola Abdallah, MD 2; Sarah Bromert, RN, BSN 1; Allison Appenfeller, RN BSN, OCN 3; Haitham Abdelhakim, MD 3; Rajat Bansal, MD 4; Zahra Mahmoudjafari, PharmD 3; Muhammad Umair Mushtaq, MD 5; Anurag K Singh, MD 6; Sunil Abhyankar, MD 4; Siddhartha Ganguly, MD, FACP 7; Joseph P. McGuirk, DO 4; Leyla Shune, MD 4;    
    Grade 3 toxicities included cardiotoxicity, neurotoxicity, and prolonged cytopenia. While careful patient selection is required to minimize toxicity, there is an unmet need to analyze outcomes of BCMA CART in patients who did not meet the KarMMA inclusion criteria, and potentially extend this therapy to those who have had fewer lines of therapy and those with comorbidities.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #451; Author: Jennifer Logue, MD 1; Lauren Peres, MPH, PhD 2; Alexandria M Shrewsbury, MS, CCRC 1; Jessica Provencher, BS 1; Taiga Nishihori, MD 1; Hien Liu, MD 1; Jason Brayer, MD, PhD 3; Omar Castaneda, MD 1; Brandon Jamaal Blue, MD 3; J. Leonel Ochoa-Bayona, MD 1; Ciara Freeman, MD 1; Hany Elmariah, MD 1; Rawan G Faramand, MD 1; Michael D Jain, MD, PhD 1; Aleksandr Lazaryan, MD, PhD, MPH 1; Nelli Bejanyan, MD 1; Lia Elena Perez, MD 1; Michael L. Nieder, MD 1; Asmita Mishra, MD 1; Joseph A. Pidala, MD, PhD 1; Marco L. Davila, MD, PhD 1; Kenneth Shain, MD, PhD 3; Rachid Baz, MD 3; Melissa Alsina, MD 1; Frederick L. Locke, MD 1; Doris K Hansen, MD 1;    
    Characterization of the risk factors and patterns of cytopenia after ide-cel in a larger number of patients should provide insights into supportive care measures to ameliorate these common complications. Additional patients and data will be presented.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Applicability of Commercial Chimeric Antigen Receptor T Cell Therapy in Relapsed and Refractory Multiple Myeloma in the Real World (TCT-ASTCT-CIBMTR 2022) -  Jan 9, 2022 - Abstract #570; Author: Smith Giri, MD 1; Susan Bal, MD 2; Kelly Godby, MD 1; Gayathri Ravi, MD 2; Deanna Clark, MBA MPH 3; Clare Ubersax, BS 3; Abigail Cooley, BS 3; Priscila White, BS 3; Grant Williams, MD MSPH 3; Luciano J. Costa, MD PhD 2;    
    Less than 10% of newly diagnosed older adults with MM are expected to be eligible for CAR-T therapy based on the current FDA approval and eligibility criteria. These findings highlight the need to explore CAR-T cell therapy in earlier lines of disease and in a population that better represents real world patients to expand the applicability of this novel treatment.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    CAR T-Cell Therapy; Journal:  Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. (Pubmed Central) -  Dec 2, 2021   
    This first-in-class therapeutic offers hope for more durable remissions, as well as better quality of life, following a single infusion in a group of patients that previously had little hope. This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, ciltacabtagene autoleucel (LCAR-B38M) / J&J
    Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma (ASH 2021) -  Nov 24, 2021 - Author: Thomas Martin; Saad Z. Usmani; Nedra Joseph; Concetta Crivera; Satish Valluri; Carolyn C. Jackson; Lucas Cohen; Sumeet Singh; Sundar Jagannath;    
    (2021) Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 1-10.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Polivy (polatuzumab vedotin) / Roche, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Kymriah (tisagenlecleucel-T) / Novartis
    CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma (ASH 2021) -  Nov 24, 2021 - Author: Tyler J D'Ovidio; Kathryn Ciccolini; Matko Kalac; Keren Osman; Amir Steinberg;    
    This has significant implications on guiding treatment decisions in future patients presenting with concomitant malignancies. Furthermore, new data from studies investigating CD19-targeted therapies' effect on myeloma will have amplified clinical relevance.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Clinical; HEOR; Journal:  Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. (Pubmed Central) -  Nov 16, 2021   
    Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For TCE patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS (SIE 2021) -  Nov 16, 2021 - Abstract #B007; Author: M. Cavo 1; A. Oriol 2; J. San-Miguel 3; A. Kansagra 4; D. Madduri 5; N. Shah 6; P. Moreau 7; I. Yakoub-Agha 8; M. Delforge 9; H. Einsele 10; H. Goldschmidt 11; K. Weisel 12; A. Rambaldi 13; D. Reece 14; P. RodríguezOtero 2; F. Petrocca 15; J. Connarn 16; P. Patel 16; L. Huang 16; T. Campbell 16; K. Hege 16; N. Munshi 17; Presentation Time: October 26, 2021; 15:40-17:10   
    P2
    Efficacy and safety results reflect prior reports and support a favorable clinical benefit-risk profile for ide-cel across the target dose levels. Accepted for presentation at EHA 2021.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Xpovio (selinexor) / Karyopharm, Menarini, Blenrep (belantamab mafodotin) / GSK
    Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry (ASH 2021) -  Nov 5, 2021 - Abstract #117; Author: Derek Tang1; Parameswaran Hari2; Karthik Ramasamy3; Katja Weisel4; Prashant Joshi, MD1; Liang Liu, MS1; Min Che1; Gabriela Hernandez5; Rafat Abonour, MD6; James W. Hardin, PhD7; Robert M. Rifkin, MD8; Sikander Ailawadhi, MD9; Hans C. Lee, MD10; Howard R. Terebelo, DO11; Brian G.M. Durie, MD12; Mohit Narang, MD13; Kathleen Toomey, MD14; Cristina Gasparetto, MD15; Lynne I. Wagner, PhD16; Sundar Jagannath, MD17; Presentation Time: December 11, 2021; 10:00-10:15   
    Among those who did receive subsequent LOTs, re-treatment with an immunomodulatory drug, PI, or anti-CD38 antibody therapy occurred, showing a lack of novel treatment options. This study suggests novel tolerable and efficacious therapeutic agents are needed to address the burden of illness in pts with MM.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma (ASH 2021) -  Nov 5, 2021 - Abstract #326; Author: David T. Melnekoff, MS1,2,3; Yogita Ghodke-Puranik, PhD2,4; Oliver Van Oekelen, MD, MSc1,2,3,5; Adolfo Aleman, MPA2,3,5; Bhaskar Upadhyaya, PhD2,5; Robert Sebra, PhD1; Sundar Jagannath, MD2,6; Alessandro Lagana, PhD1,2,7; Samir Parekh, MD2,5,8; Presentation Time: December 11, 2021; 16:15-16:30   
    Targeting the MCL-1/BCL-2 axis may augment CAR-T efficacy by sensitizing tumor cells and enhancing the effect of CAR-T killing. We will confirm these findings in a longitudinal cohort of BMMC/PBMC CITE-seq patients (n=23) and will present results at the conference.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma (ASH 2021) -  Nov 5, 2021 - Abstract #548; Author: Noopur S. Raje, MD1; Nina Shah, MD2; Sundar Jagannath, MD3; Jonathan L. Kaufman, MD4; David S. Siegel, MD, PhD5; Nikhil C. Munshi, MD, PhD6; Jacalyn Rosenblatt, MD7; Yi Lin, MD, PhD8; Andrzej Jakubowiak9; Alison Timm, MA10; Ashish Yeri, PhD10; Nathan Martin, PhD11; Timothy B. Campbell, MD, PhD11; Olivia Finney, PhD10; Anna Truppel-Hartmann, MD10; Fabio Petrocca, MD10; Jesús G. Berdeja12; Melissa Alsina, MD13; Presentation Time: December 12, 2021; 16:45-17:00   
    P1
    Efficacy results are encouraging with a median DOR estimate of 17M, CR rate continues to mature. Patients with higher levels of proliferative, less differentiated memory like CAR+ T cells at peak expansion are more likely to experience prolonged DOR, continuing to support the hypothesis that the memory like T cell phenotype associated with bb21217 results in prolonged DOR.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Breyanzi (lisocabtagene maraleucel) / BMS, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies (ASH 2021) -  Nov 5, 2021 - Abstract #566; Author: Samer Al Hadidi, MD, MSc1; Carolina Schinke, MD2; Sharmilan Thanendrarajan, MD2; Maurizio Zangari, MD, FACP3; Frits van Rhee, MD PhD2; Presentation Time: December 12, 2021; 16:45-17:00   
    CONCLUSIONS Blacks are under-represented in clinical trials that supported CAR-T therapies for various hematological malignancies especially in MM. Efforts should be made to enroll more Blacks in clinical trials that include novel, potentially beneficial CAR-T products.
  • ||||||||||  SC-DARIC33 / 2seventy bio
    Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin (ASH 2021) -  Nov 5, 2021 - Abstract #905; Author: Jacob S. Appelbaum, MD, PhD1; April Price2; Joy Zhang2; Kaori Oda3; Sumati Sundaram2; Paula Lewis, PhD2; Sanela Bilic, PharmD, MBA4; Giacomo Tampella, PhD3; Dong Xia2; Anne-Rachel Krostag, BS5; Pauline So2; Unja Martin5; Wai-Hang Leung, PhD5; Alexander Astrakhan, PhD5; Mark Pogson, PhD5; Jordan Jarjour, PhD5; Josh Gustafson, PhD6; Michael CV Jensen, MD3; Presentation Time: December 13, 2021; 19:15-19:30   
    Peripheral blood samples will be monitored for CD33+ myeloid cell recovery after cessation of RAPA dosing. These data will establish safety and support the feasibility of SC-DARIC33 CAR T cells to be reversibly modulated in an “OFF-ON-OFF” fashion by intermittent low-dose RAPA administration.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini
    Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment (ASH 2021) -  Nov 5, 2021 - Abstract #2751; Author: Muhamed Baljevic, MD1; Cristina Gasparetto, MD2; Gary J. Schiller, MD3; Sascha A. Tuchman, MD4; Natalie S. Callander, MD5; Suzanne Lentzsch, MD, PhD6; Jorge Monge, MD7; Rami Kotb, MD8; Nizar J. Bahlis, MD9; Darrell White, MD10; Christine I. Chen, MD11; Heather J. Sutherland, MD, PhD, FRCPC12; Sumit Madan, MD13; Richard Leblanc, MD, FRCPC14; Michael Sebag, MD, PhD15; Christopher P. Venner, MD16; William I. Bensinger, MD17; Noa Biran, MD18; Andrew DeCastro, PhD19; Dane R. Van Domelen, PhD19; Ohad S. Bentur, MD MHA19; Chris Zhang, MD19; Jatin J. Shah, MD19; Sharon Shacham, PhD, MBA19; Michael G. Kauffman, MD, PhD19; Brea Lipe, MD20; Presentation Time: December 12, 2021; 18:00-20:00   
    P1b/2
    Conclusions In this follow-up cohort of heavily pretreated pts, a majority of whom with MM refractory to ADC-BCMA, we demonstrate impressive potency and durability of the X-based treatments, particularly as compared to that of their prior anti-BCMA therapies. These data support the rationale for the development of novel regimens containing X plus immunomodulatory drugs or proteasome inhibitors in earlier lines of therapy, including first relapse, and further suggest their strong value in the emerging BCMA RRMM space.
  • ||||||||||  lenalidomide / Generic mfg.
    Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD) (ASH 2021) -  Nov 5, 2021 - Abstract #3786; Author: Luciano J. Costa, MD, PhD1,2,3; Robert Frank Cornell, MD4; Natalie S. Callander, MD5; Saurabh Chhabra, MD, MS6; Michaela Liedtke, MD7; Ankit Kansagra, MD8; Kelly N. Godby, MD2; Susan Bal, MD9; Smith Giri, MD, MS10; Ehsan Malek, MD11,12; Yubin Kang, MD13; Ravi Vij, MD14,15; Saad Z. Usmani, MD MBA FACP16; Parameswaran Hari17; Shaji K Kumar, MD18; Presentation Time: December 13, 2021; 18:00-20:00   
    Patients with TCR MM have a uniformly low chance of response to subsequent conventional therapy with short PFS and OS even when not penta-exposed or penta-refractory. This dataset provides efficacy benchmark for new therapies being developed in this setting.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma (ASH 2021) -  Nov 5, 2021 - Abstract #3839; Author: Jessica S. Little, MD1,2,3; Parth Shah, MD1,2; Adam S. Sperling, MD, PhD1,2; Andrew R. Branagan, MD, PhD1,4; Omar Nadeem, MD1,2; Andrew J. Yee, MD1,5; Noopur S. Raje, MD1,5; Nikhil C. Munshi, MD, PhD1,2; Sarah Hammond, MD1,2,5,6; Presentation Time: December 13, 2021; 18:00-20:00   
    P1,P2
    Bacterial infections were the most common, and there were 5 life-threatening bacterial infections within the first 30 days after infusion. Notably, patients in this group experienced only 1 fungal infection, despite no patients receiving antifungal prophylaxis.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Real-World Applicability of Commercial Chimeric Antigen Receptor T Cell Therapy Among Older Adults with Relapsed and/or Refractory Multiple Myeloma (ASH 2021) -  Nov 5, 2021 - Abstract #4107; Author: Smith Giri, MD, MS1; Susan Bal, MD2; Kelly N. Godby, MD3; Gayathri Ravi, MD4; Deanna Clark, MBA, MPH1; Clare Ubersax, BS1; Abigail Cooley, BS3; Priscila White, BS3; Sunil Rangarajan, MD5; Grant R Williams, MD MSPH6; Luciano J. Costa, MD, PhD7; Presentation Time: December 13, 2021; 18:00-20:00   
    Meanwhile a much higher proportion of patients die before reaching CAR-T eligibility. These findings highlight the need to explore CAR-T cell therapy in earlier lines of disease and in a population that better represents real world patients to expand the applicability of this novel treatment.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis (DGHO 2021) -  Oct 7, 2021 - Abstract #ep322; Author: Einsele H.1; Berdeja J.2; Raje N.S.3; Siegel D.S.4; Lin Y.5; Anderson, Jr L.D.6; Rodriguez-Otero P.7; Manier S.8; Cavo M.9; Truppel-Hartmann A.10; Rowe E.11; Sanford J.11; Wang J.11; Campbell T.B.11; Jagannath S.12;    
    P2
    Median PFS was 8.6 mo (95% CI, 4.9-12.2) in pts aged ≥65 y and 10.2 mo (95% CI, 3.1-12.3) in pts aged ≥70 y. No new safety signals were observed. These results show deep and durable responses with ide-cel treatment and a manageable safety profile in triple-class exposed pts with RRMM aged ≥65 y and ≥70 y, comparable with outcomes observed in the overall ide-cel-treated population.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Emerging Cardiovascular Side Effects of Selective and Non-Selective Immunotherapies in Cancer Patients: 2021 Results from the Global WHO Database (AHA 2021) -  Sep 24, 2021 - Abstract #VMP74; Author: Astha Prasai; Saraswati Pokharel; Umesh Sharma; Univ at Buffalo, BUFFALO, NY; Roswell Park Cancer Inst, Buffalo, NY; Univ at Buffalo, BUFFALO, NY; Presentation Time: November 13, 2021; 08:00-17:30   
    A propensity analysis demonstrated ICIs to be associated with autoimmunity-related ADRs, whereas ACTs were associated with acute cytokine release-related ADRs. Using a large-scale global WHO data platform, we have identified unique tendencies for cardiovascular ADRs resulting from non-selective (ICIs) and highly-selective (ACTs) immunotherapies for cancer: the former is associated with serious autoimmune effects, and the latter is associated with acute cytokine-release-related ADRs.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    KarMMa study: Analysis of high-risk patients with relapsed and refractory multiple myeloma treated with the CAR-T cell therapy Idecabtagen Vicleucel (Ide-Cel, bb2121) (DGHO 2021) -  Sep 20, 2021 - Abstract #V320; Author: Goldschmidt H.1; Raje N.S.2; Siegel D.3; Jagannath S.4; Lonial S.5; Munshi N.C.6; Moreau P.7; Cavo M.8; Truppel-Hartmann A.9; Rowe E.10; Huang L.10; Agarwal A.10; Wang J.10; Campbell T.B.10; San-Miguel J.11; Reece D.E.12; Presentation Time: October 01, 2021; 15:30-15:42   
    P2
    Deep and durable responses were observed in most subgroups, even in those with the highest risk, including pts with more aggressive disease features (EMD, high-risk cytogenetics, high tumor burden), and those who received bridging therapy or> 1 prior regimes per year. [Table 1]
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides, Xpovio (selinexor) / Karyopharm, Menarini, Blenrep (belantamab mafodotin) / GSK, Sarclisa (isatuximab-irfc) / Sanofi, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Journal; Review:  Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. (Pubmed Central) -  Sep 19, 2021   
    New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.
  • ||||||||||  T-cell receptor therapy / Regeneron, 2seventy bio
    [VIRTUAL] Analysis of scRNAseq from the human thymus nominates genes potentially missing from central tolerance of cytotoxic T cells (ITOC 2021) -  Sep 16, 2021 - Abstract #P03.07; Author: L Blumenberg; G Atwal; A Dhanik;    
    We used cell- and read-level subsampling to estimate whether a sufficient number of cells and reads had been captured to support categorizing a gene as non-expressed in mTECs. We also examined the expression of the genes not expressed in mTECs in other healthy tissues, and found their expression was almost exclusively restricted to the testis (an immune-privileged site) and the liver (a site of peripheral tolerance) Conclusions Altogether, these analyses establish a strategy for determining if a data set has sufficient depth to estimate the total number of genes expressed and secondly define a key list of genes that are not expressed during central tolerization of T cells, which represent a compelling list of possible cancer immunotherapy targets.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, P-BCMA-101 / Poseida Therap, orvacabtagene autoleucel (JCARH125) / BMS, PBCAR269A / Precision BioSci, bb21217 / BMS, 2seventy bio, ciltacabtagene autoleucel (LCAR-B38M) / J&J, ALLO-715 / Allogene Therap, CTX120 / CRISPR Therap
    [VIRTUAL] BCMA-Directed CAR T-Cells: Early Results and Future Directions (SOHO 2021) -  Sep 6, 2021 - Abstract #EXABS-MM-212; Author: Jesús G. Berdeja1;    
    Despite these impressive results, however, patients with MM continue to relapse. Moving these therapies earlier in the course of the disease, continued refinement of next-generation products, and rational combination strategies that may defer or prevent relapse should continue to improve on these results with the goal of finally reaching that elusive cure.